Publication:
Prognostic factors of tumefactive demyelinating lesions and differential features for multiple sclerosis in etiology

dc.contributor.authorSarıdaş, Furkan
dc.contributor.authorMesut, Gizem
dc.contributor.authorCeylan, Ceren Yayla
dc.contributor.authorÖzpar, Rıfat
dc.contributor.authorÖzsen, Mine
dc.contributor.authorKoç, Emine Rabia
dc.contributor.authorTolunay, Şahsine
dc.contributor.authorHakyemez, Bahattin
dc.contributor.authorTuran, Ömer Faruk
dc.contributor.buuauthorSARIDAŞ, FURKAN
dc.contributor.buuauthorMESUT, GİZEM
dc.contributor.buuauthorYAYLA CEYLAN, CEREN
dc.contributor.buuauthorÖZPAR, RİFAT
dc.contributor.buuauthorÖZŞEN, MİNE
dc.contributor.buuauthorKOÇ, EMİNE RABİA
dc.contributor.buuauthorTOLUNAY, ŞAHSİNE
dc.contributor.buuauthorHAKYEMEZ, BAHATTİN
dc.contributor.buuauthorTURAN, ÖMER FARUK
dc.contributor.departmentTıp Fakültesi
dc.contributor.departmentNöroloji Ana Bilim Dalı
dc.contributor.departmentRadyoloji Ana Bilim Dalı
dc.contributor.departmentPatoloji Ana Bilim Dalı
dc.contributor.orcid0000-0001-5945-2317
dc.contributor.orcid0009-0006-2052-6335
dc.contributor.orcid0000-0001-6649-9287
dc.contributor.orcid0000-0002-5771-7649
dc.contributor.orcid0000-0002-0264-7284
dc.contributor.researcheridAAI-1612-2021
dc.contributor.researcheridAAI-2318-2021
dc.contributor.researcheridHSB-2700-2023
dc.contributor.researcheridAAH-5062-2021
dc.contributor.researcheridA-7083-2015
dc.contributor.researcheridAAI-1609-2021
dc.contributor.researcheridKEU-7785-2024
dc.contributor.researcheridKJX-0101-2024
dc.contributor.researcheridJDI-6091-2023
dc.date.accessioned2025-02-11T11:31:15Z
dc.date.available2025-02-11T11:31:15Z
dc.date.issued2024-03-08
dc.description.abstractBackground: Many different pathologies may underlie tumefactive demyelinating lesions. Identifying clinical and radiologic distinguishing features before pathologic examination is essential for diagnosis and treatment. In this study, we aimed to determine the clinical and radiologic features affecting the etiology and disease course of patients with tumefactive lesions (TDL). Materials and Methods: We included 35 clinicoradiologically or histologically diagnosed TDL patients in our center over 11 years. Patient records were retrospectively evaluated and recorded. Clinical features, cerebral neuroimaging, and histologic biopsy preparations, if any, were assessed by three independent neurologists, two neuroradiologists, and two pathologists at admission and follow-up, respectively. Results: The mean age of patients with TDL was 40.02 +/- 14.40 years. Symptom onset was 15 (1-365) days. The most common complaints at initial presentation were hemiparesis or hemiplegia, sensory complaints, and cognitive impairment (aphasia or apraxia). The lesions were most commonly localized in the frontal lobe (42.9 %). Mass effect was 17.1 %, edema 60 %, diffusion restriction 62.1 %, and contrast enhancement 71.9 % (mostly ring-shaped (68.8 %)) on MR images. Acute onset and OCB type-2 positivity were associated with MS diagnosis. On the other hand, CSF protein levels above 45 mg/dL were found to be related to non-MS etiologies. Only the predominance of aphasia or apraxia at onset was a risk factor for early high disability (EDSS>4; 3rd month). Subacute-chronic onset, being older than 40 years, or having brainstem symptoms at onset were independent risk factors for late high disability (2nd year). Conclusion: Acute onset or OCB type 2 positivity is a clue for early diagnosis of MS, while elevated CSF protein is a clue for demyelinating diseases other than MS. Presentation with cognitive dysfunction at onset is an independent risk factor for early disability, while age above 40 years, subacute-chronic presentation and brainstem findings at presentation are independent risk factors for late disability.
dc.identifier.doi10.1016/j.msard.2024.105537
dc.identifier.issn2211-0348
dc.identifier.scopus2-s2.0-85187001737
dc.identifier.urihttps://doi.org/10.1016/j.msard.2024.105537
dc.identifier.urihttps://www.sciencedirect.com/science/article/pii/S2211034824001160
dc.identifier.urihttps://hdl.handle.net/11452/50274
dc.identifier.volume85
dc.identifier.wos001202501100001
dc.indexed.wosWOS.SCI
dc.language.isoen
dc.publisherElsevier Sci Ltd
dc.relation.journalMultiple Sclerosis and Related Disorders
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectMultiple sclerosis
dc.subjectCsf
dc.subjectOcb
dc.subjectMri
dc.subjectTumefactive demyelinating lesions
dc.subjectNeurosciences & neurology
dc.titlePrognostic factors of tumefactive demyelinating lesions and differential features for multiple sclerosis in etiology
dc.typeArticle
dspace.entity.typePublication
local.contributor.departmentTıp Fakültesi/Nöroloji Ana Bilim Dalı
local.contributor.departmentTıp Fakültesi/Radyoloji Ana Bilim Dalı
local.contributor.departmentTıp Fakültesi/Patoloji Ana Bilim Dalı
local.indexed.atWOS
local.indexed.atScopus
relation.isAuthorOfPublication80b8fcdf-d916-4b3e-a7cb-00aebac954a7
relation.isAuthorOfPublicationdd85479d-e8ea-4655-a67b-6ad103510829
relation.isAuthorOfPublication9f4ac9c3-75c4-45e4-ad98-54b6300aa1df
relation.isAuthorOfPublication597eca82-1312-4286-b1b1-b47aec03619c
relation.isAuthorOfPublication736328be-f008-46e1-825a-46199f11dad9
relation.isAuthorOfPublication53dede82-e480-4f98-917e-74465ab90060
relation.isAuthorOfPublication13dc6562-e9fe-42fa-8973-dcd80444844e
relation.isAuthorOfPublication9ad8c0f1-5154-4a82-b029-77c58cb35066
relation.isAuthorOfPublication75b4302d-5005-4298-900e-7a9e16afa9e2
relation.isAuthorOfPublication.latestForDiscovery80b8fcdf-d916-4b3e-a7cb-00aebac954a7

Files